« Back
Home /
KW-2449

KW-2449

Item no.	M1815-200mg
Manufacturer	AbMole
CASRN	1000669-72-6
Amount	200mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	0,988
Citations	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Sato T, et al . Blood. 2011 Mar 24,117(12):3286-93. PMID: 21263155 . FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Pratz KW, et al . Blood. 2010 Feb 18,115(7):1425-32. PMID: 20007803 . KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Shiotsu Y, et al . Blood. 2009 Aug 20,114(8):1607-17. PMID: 19541823 . A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Pratz KW, et al . Blood. 2009 Apr 23,113(17):3938-46. PMID: 19029442 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	KW2449
Similar products	KW-2449, KW2449
Available
Molecular Weight	332, 4
Solubility	DMSO 57 mg/mL
Bioactivity information	KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1815-200mg-safety-datasheet.pdf